Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR-T vs ASCT in Newly Diagnosed Multiple Myeloma
NCT07070934Phase 2Not yet recruiting
- Sponsor
- Xuzhou Medical University
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
01
Overview
A Phase 2 trial of anti-BCMA CAR-T in multiple myeloma (MM), sponsored by Xuzhou Medical University. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
anti-BCMA CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07070934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070934.